Arvinas (ARVN) to Release Quarterly Earnings on Wednesday

Arvinas (NASDAQ:ARVN - Get Free Report) is scheduled to be announcing its earnings results before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($1.08) by $0.59. The business had revenue of $76.50 million for the quarter, compared to analyst estimates of $33.27 million. The firm's quarterly revenue was up 40.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.25) earnings per share. On average, analysts expect Arvinas to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Stock Performance

NASDAQ:ARVN traded down $0.05 during trading hours on Wednesday, hitting $26.52. 690,765 shares of the company's stock traded hands, compared to its average volume of 718,597. The firm has a market cap of $1.81 billion, a P/E ratio of -4.47 and a beta of 1.97. Arvinas has a twelve month low of $13.57 and a twelve month high of $53.08. The stock's fifty day moving average price is $25.40 and its two-hundred day moving average price is $28.21.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ARVN shares. Oppenheimer dropped their target price on Arvinas from $70.00 to $50.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 31st. Barclays decreased their price target on Arvinas from $60.00 to $48.00 and set an "overweight" rating for the company in a research note on Wednesday, July 31st. Wedbush reiterated an "outperform" rating and set a $57.00 price target on shares of Arvinas in a research note on Tuesday, July 30th. HC Wainwright reiterated a "buy" rating and set a $87.00 price target on shares of Arvinas in a research note on Thursday, August 1st. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a research note on Monday, September 9th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $57.50.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.